AMICUS THERAPEUTICS THE OUTSTANDING PHARMACEUTICAL COMPANY

With the so much increase in diseases outbreak in the world, a lot of research is being done to curb or cure this diseases. Most of the companies in this medical industries try as much as possible to be specific in their areas of specialization (Yahoo Finance). Amicus Therapeutics is one of the companies in this industry. It focuses on specific diseases that are not so common uncommon and fondling. This company particularly deals with lysosomal storage conditions and the products of this company is founded with the main focus being the development of enzyme replacement remedies.

 

 

Amicus Therapeutics is located in Cranbury, New Jersy, America and it deals with biopharmaceuticals. The company was allowed to issue stock for sale to the general public in 2007 under the National Association of Securities Dealer Automated Quotation (NASDAQ) system trading symbol FOLD. Amicus Therapeutics Company made this great achievement after pre arranged offering and preceding withdrawal in 2006. They were supported by venture capital firms such as Canaan partners, radius ventures and New Enterprise Associates.

 

 

In the year 2014, Amicus Therapeutics was found to be the best in all the pharmaceutical industries. By February the same year, their most advanced candidate was Migalastat whose trade name was Galafold. In the improvement of migalastat, Amicus Therapeutics worked in partnership with other pharmaceuticals such as GlaxoSmithKline and JCR. This was done by co-formulating with recombinant alpha-galactosidase. Their partnership started in 2010 and ended in 2013 a period of three years. The company relies on contract manufacturing alone.

 

 

For purposes of growth and development, Amicus Therapeutics opened another research site in San Diego. Towards the end of 2009, the company decided to end its multi-year partnership agreement with The Shire. In support of Amicus Therapeutics partnership with David Gefen School of Medicine, Michael J. Fox Foundation gave the company a grant of US$ 500 000. In support of preclinical work that Amicus Therapeutics Company did in partnership with Icahn School of medicine, they received US$ 210 300 grant from the Alzheimer’s Drug Discovery Foundation. In 2015 the company too received intellectual and propriety materials for purposes of enzyme replacement management.

More about Amicus Therapeutics at https://www.indeed.com/q-Amicus-Therapeutics-l-Cranbury,-NJ-jobs.html